CompanyGraph
ChemoMetec A/S
CHEMM · Nasdaq Copenhagen · Denmark
Price data from its CHEMMc listing on CBOE
chemometec.comFinancials as of FY2025
What stands out
- Valued far above the size of its business
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.95B, above the global median of $1.15B
- PositionOperating margin is 48.4%, higher than 95% of its Medical Devices peers (median 8.1%)
- Interpretations8 currently firing — 8
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.48%
Annual Rate
DKK 7.00Paid unknown
Payout Ratio
68.8%Moderate
Last Ex-Dividend
Oct 10, 2025
The reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
12.49BDKK1.95B · vs all stocks (USD)
Trailing P/E
47.49xvs Medical Devices peers
Revenue (TTM)
493.12MDKK77.01M · vs all stocks (USD)
Profit Margin
35.90%vs Medical Devices peers
Beta
1.38xvs all stocks
52-Week Change
-7.43%vs all stocks
Forward Annual Dividend Yield
1.48%vs all stocks
Market Capitalization
12.49BDKK1.95B · vs all stocks (USD)
Enterprise Value
8.14BDKK1.27B · vs all stocks (USD)
Trailing P/E
47.49xvs Medical Devices peers
Forward P/E
38.60xvs Medical Devices peers
Price to Sales (TTM)
17.05xvs Medical Devices peers
Price to Book (MRQ)
12.88xvs Medical Devices peers
Enterprise to Revenue
16.50xvs Medical Devices peers
Enterprise to EBITDA
33.32xvs Medical Devices peers
Profit Margin
35.90%vs Medical Devices peers
Operating Margin
48.42%vs Medical Devices peers
Return on Assets (TTM)
19.08%vs Medical Devices peers
Return on Equity (TTM)
28.31%vs Medical Devices peers
Revenue (TTM)
493.12MDKK77.01M · vs all stocks (USD)
Revenue per Share (TTM)
28.33DKKUpdated Aug 21, 2026Quarterly Revenue Growth
-1.00%vs Medical Devices peers
Gross Profit (TTM)
471.14MDKK73.58M · vs all stocks (USD)
EBITDA (TTM)
262.10MDKK40.94M · vs all stocks (USD)
Net Income (TTM)
177.03MDKK27.65M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-9.10%vs Medical Devices peers
Operating Cash Flow (TTM)
210.08MDKK32.81M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
123.55MDKK19.30M · vs all stocks (USD)
Forward Annual Dividend Rate
7.00DKKUpdated Aug 21, 2026Forward Annual Dividend Yield
1.48%vs all stocks
Trailing Annual Dividend Rate
7.00DKKUpdated Aug 21, 2026Trailing Annual Dividend Yield
1.48%vs all stocks
Payout Ratio
68.83%vs Medical Devices peers
Revenue
495.57MDKKFY2025 · Jun 30, 2025Cost of Goods Sold
30.06MDKKFY2025 · Jun 30, 2025Gross Profit
465.51MDKKFY2025 · Jun 30, 2025Operating Income
236.52MDKK36.94M · vs all stocks (USD)
Pre-tax Income
240.01MDKKFY2025 · Jun 30, 2025Income Tax Expense
53.61MDKKFY2025 · Jun 30, 2025Net Income
186.41MDKKFY2025 · Jun 30, 2025EBIT
240.57MDKKFY2025 · Jun 30, 2025EBITDA (Income Statement)
262.10MDKKFY2025 · Jun 30, 2025Other Operating Expenses
53.55MDKKFY2025 · Jun 30, 2025Non-operating Interest Income
5.90MDKKFY2025 · Jun 30, 2025Non-operating Interest Expense
558.00KDKKFY2025 · Jun 30, 2025EPS (Basic)
10.71DKKFY2025 · Jun 30, 2025EPS (Diluted)
10.71DKKFY2025 · Jun 30, 2025Basic Shares Outstanding
17.40MSharesFY2025 · Jun 30, 2025Diluted Shares Outstanding
17.40MSharesFY2025 · Jun 30, 2025Net Income from Continuing Operations
236.52MDKKFY2025 · Jun 30, 2025Preferred Stock Dividends
0.00DKKFY2025 · Jun 30, 2025Operating Cash Flow
236.52MDKKFY2025 · Jun 30, 2025Free Cash Flow
206.65MDKKFY2025 · Jun 30, 2025Cash & Cash Equivalents (End of Period)
341.85MDKKFY2025 · Jun 30, 2025Starting Profit (CF Statement)
236.52MDKKFY2025 · Jun 30, 2025Capital Expenditures
-29.87MDKKFY2025 · Jun 30, 2025Net Intangibles (CF)
-34.87MDKKFY2025 · Jun 30, 2025Net Acquisitions
-20.79MDKKFY2025 · Jun 30, 2025Sale of Investments
0.00DKKFY2025 · Jun 30, 2025Net Investing Cash Flow
-50.65MDKKFY2025 · Jun 30, 2025Long-term Debt Issuance
524.00KDKKFY2025 · Jun 30, 2025Net Short-term Debt Issuance
-5.40MDKKFY2025 · Jun 30, 2025Common Dividends Paid
-69.60MDKKFY2025 · Jun 30, 2025Net Financing Cash Flow
-74.48MDKKFY2025 · Jun 30, 2025Shares Outstanding
17.40MSharesUpdated Aug 21, 2026Float Shares
16.74MSharesUpdated Aug 21, 2026% Held by Insiders
3.73%vs all stocks
% Held by Institutions
53.60%vs all stocks
Total Cash (MRQ)
274.66MDKK42.90M · vs all stocks (USD)
Total Cash per Share (MRQ)
15.78DKKUpdated Aug 21, 2026Total Debt (MRQ)
5.21MDKK813.85K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0080xvs Medical Devices peers
Current Ratio (MRQ)
3.93xvs Medical Devices peers
Book Value per Share (MRQ)
37.50DKKUpdated Aug 21, 2026Total Assets
828.05MDKK129.32M · vs all stocks (USD)
Total Current Assets
543.16MDKKFY2025 · Jun 30, 2025Total Liabilities
154.69MDKKFY2025 · Jun 30, 2025Total Non-current Assets
284.88MDKKFY2025 · Jun 30, 2025Total Non-current Liabilities
7.70MDKKFY2025 · Jun 30, 2025Total Current Liabilities
146.99MDKKFY2025 · Jun 30, 2025Cash
341.85MDKKFY2025 · Jun 30, 2025Cash & Cash Equivalents
341.85MDKKFY2025 · Jun 30, 2025Accounts Receivable
79.62MDKKFY2025 · Jun 30, 2025Inventory
109.34MDKKFY2025 · Jun 30, 2025Accounts Payable
16.08MDKKFY2025 · Jun 30, 2025Short-term Debt
3.39MDKKFY2025 · Jun 30, 2025Other Current Liabilities
1.00KDKKFY2025 · Jun 30, 2025Long-term Debt
3.02MDKKFY2025 · Jun 30, 2025Other Non-current Liabilities
1.00KDKKFY2025 · Jun 30, 2025Common Stock (Book)
17.40MDKKFY2025 · Jun 30, 2025Retained Earnings
542.88MDKKFY2025 · Jun 30, 2025Total Shareholders' Equity
673.36MDKK105.16M · vs all stocks (USD)
52-Week Low
235.20DKKUpdated Aug 21, 202652-Week High
804.00DKKUpdated Aug 21, 202652-Week Change
-7.43%vs all stocks
Beta
1.38xvs all stocks
50-Day MA
409.16DKKUpdated Aug 21, 2026200-Day MA
481.49DKKUpdated Aug 21, 2026Avg 10-Day Volume
85.40KSharesUpdated Aug 21, 2026Avg 30-Day Volume
55.07KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
10.17DKKUpdated Aug 21, 20268 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 48.4%, higher than 95% of its Medical Devices peers (median 8.1%)Significant
Operating margin: 0.48Industry median: 0.08Industry P95: 0.34Peers compared: 102
Profit margin is 35.9%, higher than 95% of its Medical Devices peers (median 4.8%)Significant
Profit margin: 0.36Industry median: 0.05Industry P95: 0.32Peers compared: 102
Return on equity is 28.3%, higher than 95% of its Medical Devices peers (median 3%)Significant
Return on equity: 0.28Industry median: 0.03Industry P95: 0.17Peers compared: 102
Return on assets is 19.1%, higher than 95% of its Medical Devices peers (median 1.9%)Significant
Return on assets: 0.19Industry median: 0.02Industry P95: 0.12Peers compared: 102
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 17.05Revenue Growth YoY: -0.01
Financial Health
High earnings qualityNotable
Earnings Quality Score: 0.93
High structural barrier to entryNotable
Barrier to Entry: 0.90
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.95B, above the global median of $1.15BNotable
Market cap (USD): 1,950,107,116.692Global Median: 1,146,734,693.424
Levered free cash flow is $19.3M, above the global median of $16.24MNotable
Levered free cash flow (USD): 19,296,741.185Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Harmony Biosciences Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Urogen Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Damora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ocular Therapeutix Inc.
Tier 1ProductionApproval-Gated PipelineRule
GH Research plc
Tier 1ProductionApproval-Gated PipelineRule
Beijing Aosaikang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Healthgen Biotechnology Corp.
Tier 1ProductionApproval-Gated PipelineRule
Galapagos NV
Tier 1ProductionApproval-Gated PipelineRuleRisk
Fagron NV
Tier 1ProductionApproval-Gated PipelineFlowRule
Tyra Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Classys Inc.
8 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Donghua Testing Technology Co., Ltd.
8 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Suzhou TFC Optical Communication Co., Ltd.
8 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels